Renata C.
- Country
- Portugal
- Department
- Hematolgy
Research Overview
- Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of Ibrutinib and Rituximab in Treatment-naïve Follicular Lymphoma Patients
- Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study of Elenestinib in Patients with Indolent Systemic Mastocytosis and Smoldering Systemic Mastocytosis
- Phase 3 Randomized Trial of Acalabrutinib, Obinutuzumab, and Venetoclax in High-Risk Chronic Lymphocytic Leukemia Patients
Data & Insights
Has run more than one trial at 15 of 177 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating Follicular Lymphoma, focusing on innovative combination therapies involving targeted agents and immunotherapy approaches. Their research explores novel treatment strategies for patients with this form of non-Hodgkin lymphoma.
- B-cell lymphoma management
- Immunotherapy applications
- Treatment-naïve patient care
Particular attention is given to evaluating treatment outcomes and progression-free survival in lymphoma patients.
Rare Hematologic Conditions
The investigator demonstrates expertise in treating Indolent Systemic Mastocytosis, a rare mast cell disorder. Their work includes evaluation of novel therapeutic agents designed specifically for this condition.
- Mast cell disorders
- Targeted therapy development
- Rare disease management
The research focuses on determining optimal treatment approaches for patients with various forms of systemic mastocytosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.